Cargando…

Anti-emicizumab antibodies do not cross-react with mim8 in vitro

Detalles Bibliográficos
Autores principales:	Valsecchi, Carla, Gualtierotti, Roberta, Arcudi, Sara, Ciavarella, Alessandro, Siboni, Simona Maria, Schiavone, Lucia, Beeg, Marten, Gobbi, Marco, Peyvandi, Flora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483040/ https://www.ncbi.nlm.nih.gov/pubmed/37694267 http://dx.doi.org/10.1016/j.rpth.2023.102161

Ejemplares similares

Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

Updates on Novel Non-Replacement Drugs for Hemophilia
por: Gualtierotti, Roberta, et al.
Publicado: (2022)

Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
por: La Mura, Vincenzo, et al.
Publicado: (2023)

Plasma Exchange in a Patient with Immune Thrombocytopenia Associated with Antiphospholipid Syndrome Hospitalized for COVID-19
por: Boggio, Federico, et al.
Publicado: (2022)

Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
por: Suffritti, Chiara, et al.
Publicado: (2023)

Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy
por: Gualtierotti, Roberta, et al.
Publicado: (2022)

Where do we stand with antithrombotic prophylaxis in patients with COVID-19?
por: Ciavarella, Alessandro, et al.
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Hemophilic arthropathy: Current knowledge and future perspectives
por: Gualtierotti, Roberta, et al.
Publicado: (2021)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Do you know this syndrome? Schimmelpenning-Feuerstein-Mims syndrome
por: Lena, Clarissa Patias, et al.
Publicado: (2019)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
por: Glonnegger, Hannah, et al.
Publicado: (2022)

Emicizumab-induced photosensitivity
por: Asensi Cantó, Pedro, et al.
Publicado: (2022)

The Forrest Mims engineer's notebook
por: Mims, Forrest M
Publicado: (1992)

Emicizumab state‐of‐the‐art update
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
por: Matsumoto, Naoki, et al.
Publicado: (2023)

Tracking Monochloramine Decomposition in MIMS Analysis
por: Roumiguières, Adrien, et al.
Publicado: (2019)

Multiscale Innovative Materials and Structures (MIMS)
por: Barretta, Raffaele, et al.
Publicado: (2021)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

The dosing conundrum of emicizumab: To waste product or not?
por: Young, Guy
Publicado: (2023)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
por: Callaghan, Michael U., et al.
Publicado: (2022)

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
por: Kruse-Jarres, Rebecca, et al.
Publicado: (2022)

MIM gives cells a sense of direction
por: Short, Ben
Publicado: (2010)

Phacomatosis pigmentokeratotica or the Schimmelpenning‐Feuerstein‐Mims syndrome?
por: Gamayunov, Boris N., et al.
Publicado: (2016)

A formal MIM specification and tools for the common exchange of MIM diagrams: an XML-Based format, an API, and a validation method
por: Luna, Augustin, et al.
Publicado: (2011)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

The Anti-Amyloidogenic Action of Doxycycline: A Molecular Dynamics Study on the Interaction with Aβ42
por: Gautieri, Alfonso, et al.
Publicado: (2019)

Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?
por: Diomede, Luisa, et al.
Publicado: (2021)

No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2
por: Peyvandi, Flora, et al.
Publicado: (2021)

The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients
por: Pagliari, Maria Teresa, et al.
Publicado: (2022)

React and React Native
por: Boduch, Adam
Publicado: (2017)

React and React Native
por: Boduch, Adam
Publicado: (2020)

Tunable Fano Resonance in Asymmetric MIM Waveguide Structure
por: Zhao, Xuefeng, et al.
Publicado: (2017)

An Infrared Ultra-Broadband Absorber Based on MIM Structure
por: Li, Meichen, et al.
Publicado: (2022)

Successful Chemical Synovectomy in a Patient with Acquired von Willebrand Syndrome with Chronic Synovitis Due to Recurrent Knee Hemarthrosis: A Case Report
por: Gualtierotti, Roberta, et al.
Publicado: (2022)

Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A
por: Spena, Silvia, et al.
Publicado: (2022)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding
por: Cugno, Massimo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u417lk9q8d9mv59r3odnodscuk